Navigation Links
Intra-Cellular Therapies Announces Positive Results with ITI-002 in Pre-Clinical Models of Parkinson's Disease
Date:10/1/2010

ge, reaching 4% of the population over 80. Mean age of onset is around 60 years, although in 5-10% of cases the onset is earlier and occurs between the ages of 20 and 50. Primary symptoms include decreased motor function caused by appearance of tremor, rigidity, bradykinesia, and postural instability.  Many patients co-morbidly exhibit impaired cognitive function, depression and excessive day time sleepiness. Dopamine replacement therapies, such as L-DOPA, are the current treatments of choice. However, with time on drug and with disease progression, these drug therapies often lose effectiveness and can cause unwanted side effects such as dyskinesias and hallucinosis.

ABOUT INTRA-CELLULAR THERAPIES

Intra-Cellular Therapies, Inc. (ITI) is a biopharmaceutical company developing novel drugs for the treatment of diseases and disorders of the Central Nervous System (CNS).  Building on the science generated from the Nobel Prize winning laboratory of Dr. Paul Greengard at The Rockefeller University, the Company develops compounds that have the potential to treat a wide range of diseases associated with the CNS, including schizophrenia, sleep disorders, Parkinson's disease and Alzheimer's disease, cognitive deficits in schizophrenia, depression and female sexual dysfunction, and other disorders pertaining to Women's Health.  To aid in the development process, ITI incorporates its CNSProfile™, a state-of-the-art platform that allows the Company to choose compounds with the strongest potential to succeed in these difficult to treat diseases.


'/>"/>
SOURCE Intra-Cellular Therapies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Intra-Cellular Therapies Reports Positive Final Results of a Phase II Clinical Trial with ITI-007 in Patients with Sleep Maintenance Insomnia
2. Circassia Initiates Phase II Trials of Novel Grass and Ragweed Allergy Therapies and Advances Phase III Plans for cat Allergy T-Cell Vaccine
3. Drug Sales in the Leukemia Market Will Be Driven By Therapies From Novartis, Bristol-Myers Squibb, Biogen Idec, Roche and Cephalon
4. Vital Therapies Expands SILVER Trial to Saudi Arabia
5. Prometheus and Tarrot Laboratories Collaborate to Identify Markers Associated With Response to Anti-TNF Therapies in Crohns Disease
6. PPTA Urges CMS for Appropriate Hospital Outpatient Reimbursement for Plasma Protein Therapies
7. US Oncology Helps Deliver Latest Cancer Therapies Through Local Community Access to Cutting Edge Research
8. NeoStem to Receive $700,000 from the U.S. Armys Medical Research and Materiel Command to Advance Adult Stem Cell Therapies in Treating Traumatic Wounds
9. New Cancer Treatments and Combination Therapies Presented by Leading Experts from the John Theurer Cancer Center at the American Society of Clinical Oncology Annual Meeting
10. ALS Therapy Development Institute and Oxford BioMedica Begin Second Phase of Collaboration to Develop Gene Therapies for Amyotrophic Lateral Sclerosis
11. 5th Annual Summit to Feature New Stem Cell Therapies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... 2014 A long-term retrospective study of ... (APBI) via interstitial brachytherapy suggests that women younger ... could be suitable to receive the treatment. Current ... these patients in the "unsuitable" category for APBI. ... meeting, Beaumont Health System,s Peter Y. Chen ...
(Date:9/17/2014)... September 17, 2014 Shimadzu ... Liquid Chromatograph (2D-LC), which offers a powerful ... matrices. The system provides a new level ... which is beneficial to scientists analyzing pharmaceutical ... natural products. , Comprehensive 2D-LC combines two ...
(Date:9/17/2014)... Hershey, PA & Rockville, MD (PRWEB) September 17, 2014 ... it won a Small Business Innovation Research (SBIR) grant ... allergy immunotherapy. The award will provide ITI with approximately ... , Tree nuts, a leading cause of food allergy, ... leading cause of anaphylaxis behind peanut allergy. Tree nut ...
(Date:9/17/2014)... SQI Diagnostics Inc. (TSX-V: SQD) (OTCQX: SQIDF), a life ... products for advanced microarray diagnostics, today announced that its ... the United States on the OTCQX ... 17, 2014 on the OTCQX under the symbol SQIDF.  ... Venture Exchange under its existing symbol SQD. ...
Breaking Biology Technology:Partial Breast Irradiation With Interstitial Brachytherapy Appears Appropriate For Women Previously Considered Unsuitable 2Partial Breast Irradiation With Interstitial Brachytherapy Appears Appropriate For Women Previously Considered Unsuitable 3Partial Breast Irradiation With Interstitial Brachytherapy Appears Appropriate For Women Previously Considered Unsuitable 4Shimadzu’s New Nexera-e Two Dimensional Comprehensive Liquid Chromatograph Empowers Laboratories to Separate Even the Most Complex Mixtures 2Immunomic Therapeutics Awarded SBIR Grant to Develop Multi-Nut Allergy Immunotherapy 2Immunomic Therapeutics Awarded SBIR Grant to Develop Multi-Nut Allergy Immunotherapy 3SQI Diagnostics to begin Trading on the OTCQX Marketplace in the United States 2SQI Diagnostics to begin Trading on the OTCQX Marketplace in the United States 3
... , ATLANTA, Sept. 14 CryoLife, Inc. ... medical device and cardiovascular tissue processing company, announced today that it ... Conference at the Grand Hyatt New York in New York City. ... executive officer of CryoLife, Inc., will present Monday, September 21 at ...
... , NATICK, Mass., Sept. ... ) today announced that it has entered into a ... company offering advanced testing solutions for urinary incontinence. ... combines staffing, equipment, supplies and results analysis, helping to ...
... , HOLDEN, Mass., Sept. ... appointment of Elkan Gamzu, Ph.D. as Chairman to its ... years of pharmaceutical and biotechnology experience and has held ... President of Project Management at Millenium Pharmaceuticals, CEO of ...
Cached Biology Technology:CryoLife to Present at UBS Global Life Sciences Conference 2Boston Scientific's Urology/Gynecology Business Forms Marketing Alliance with Bladder Health Network 2Boston Scientific's Urology/Gynecology Business Forms Marketing Alliance with Bladder Health Network 3Elkan Gamzu, Ph.D. Joins Hygeia Therapeutics' Board of Directors as Chair 2
(Date:9/17/2014)... "Nature has developed, very cleverly, some lessons on how ... design," said Joseph Shaw, director of the Optical Technology ... and structures at the nanoscale, we,ll discover them." , ... in August during a conference called "The Nature of ... Liang of the University of Arizona College of Optical ...
(Date:9/17/2014)... New research from the Copenhagen Centre for Social Evolution ... evolutionary theory that birth weight and -length can partially ... disorders such as autism and schizophrenia later in life. ... births, and subsequent hospital diagnoses for up to 30 ... factors. The study is published today in the ...
(Date:9/17/2014)... have obtained the first partial genome sequence of an ... at the site of the Montsoriu Castle in Girona, ... closely related to today,s Iberian pig. Researchers also discard ... Iberian pigs. , The study, published in Heredity ... species, and particularly on that of the Iberian breed, ...
Breaking Biology News(10 mins):Nature's designs inspire research into new light-based technologies 2Nature's designs inspire research into new light-based technologies 3Size at birth affects risk of adolescent mental health disorders 2Size at birth affects risk of adolescent mental health disorders 3Iberian pig genome remains unchanged after 5 centuries 2
... of the Santa Cruz Mountains two closely related species of ... very different social lives. The California mouse ( Peromyscus californicus ... mouse ( Peromyscus maniculatus ) is sexually promiscuous. Researchers ... differences in sexual behavior impact the bacteria hosted by each ...
... toward helping people grow big, strong muscles without needing to ... blocking the function of a protein called Grb10 while mice ... muscular than their normal counterparts. This discovery appears in the ... . Outside of aesthetics, this study has important implications for ...
... to common environmental chemicals - polyfluoroalkyl compounds (PFCs) - ... at 20 months of age, according to a study ... online in the August 30 edition of Environmental ... production of fluoropolymers and are found widely in protective ...
Cached Biology News:Monogamy and the immune system 2Monogamy and the immune system 3Monogamy and the immune system 4Monogamy and the immune system 5'Hulk' protein, Grb10, controls muscle growth 2Chemical exposure in the womb from household items may contribute to obesity 2
... The TargeTron(TM) Gene Knockout System provides optimized ... specific disruption of bacterial genes by insertion ... the retrohoming ability of group II introns ... re-target the TargeTron group II intron for ...
... a partial recombinant MAK. Immunogen: ... partial recombinant protein with GST tag. ... Accession: BC039825 Protein Accession ... 154235, GeneID: 4117 ...
...
Mouse polyclonal antibody raised against a partial recombinant DDEF2. NCBI Entrez Gene ID = 8853...
Biology Products: